Hansa Biopharma AB (CHIX:HNSAS) Institutional Ownership: 20.29% (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:HNSAS Hansa Biopharma AB CHIX:HNSAS
43 GF Score
Price kr25.64
GF Value kr14.50
! 7 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Institutional Ownership?

Hansa Biopharma AB CHIX:HNSAS 43 Institutional Ownership is 20.29% as of Jul. 27, 2026. GuruFocus rates CHIX:HNSAS with a GF Score™ of 43/100 and a GF Value™ of kr14.50. The stock has 7 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Hansa Biopharma AB's institutional ownership is 20.29%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Hansa Biopharma AB's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Hansa Biopharma AB's Float Percentage Of Total Shares Outstanding is 0.00%.

Hansa Biopharma AB Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Institutional Ownership Chart

Hansa Biopharma AB Historical Data

The historical data trend for Hansa Biopharma AB can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 4.70 16.83 18.31 18.01 18.52 19.38 20.40 20.41 20.27 20.29
CHIX:HNSAS
43GF Score
Hansa Biopharma AB CHIX:HNSAS
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 20.29% mean?
Hansa Biopharma AB (CHIX:HNSAS) has a Institutional Ownership of 20.29% as of Jul. 27, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Institutional Ownership too high?
Hansa Biopharma AB's current Institutional Ownership is 20.29%. Overall, Hansa Biopharma AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Institutional Ownership compare to VRTX and REGN?
Hansa Biopharma AB's Institutional Ownership of 20.29% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Institutional Ownership is 20.29%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Hansa Biopharma AB (CHIX:HNSAS) has a current Institutional Ownership of 20.29%. The stock's GF Value™ is kr14.50, compared to a current price of kr25.64 — trading 76.8% above its estimated fair value. The current Institutional Ownership is 20.29%. Hansa Biopharma AB's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Hansa Biopharma AB (CHIX:HNSAS), the current Institutional Ownership is 20.29% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (CHIX:HNSAS) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of kr25.64 is trading 76.8% above its estimated GF Value™ of kr14.50.

Key valuation signals for CHIX:HNSAS:

  • Institutional Ownership: 20.29%
  • GF Value™: kr14.50 vs. price of kr25.64 (76.8% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the CHIX:HNSAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
43GF Score

Get the complete analysis for CHIX:HNSAS

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr25.64
Price
kr14.50
GF Value